These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3842220)

  • 1. Phase II clinical study of implanted norethindrone pellets for longterm contraception in women. Program for Applied Research on Fertility Regulation.
    Adv Contracept; 1985 Dec; 1(4):295-304. PubMed ID: 3842220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contraceptive efficacy of bioabsorbable pellets of norethindrone (NET) as subcutaneous implants: phase II clinical study.
    Singh M; Saxena BB; Landesman R; Ledger WJ
    Adv Contracept; 1985 Jun; 1(2):131-49. PubMed ID: 3842214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable norethindrone (NET:cholesterol) contraceptive implants: phase II-A: a clinical study in women.
    Singh M; Saxena BB; Raghubanshi RS; Ledger WJ; Harman SM; Leonard RJ
    Contraception; 1997 Jan; 55(1):23-33. PubMed ID: 9013058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter clinical trial of implanted norethindrone pellets for long-acting contraception in women. Program for Applied Research on Fertility Regulation.
    Contraception; 1984 Sep; 30(3):239-52. PubMed ID: 6509979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subdermal norethindrone pellets -- a method for contraception?
    Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
    Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
    Raymond EG; Singh M; Archer DF; Saxena BB; Baker J; Cole D
    Fertil Steril; 1996 Dec; 66(6):954-61. PubMed ID: 8941061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: Phase I. Clinical study.
    Gupta GN; Saxena BB; Landesman R; Ledger WJ
    Fertil Steril; 1984 May; 41(5):726-31. PubMed ID: 6714449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pure crystalline estradiol pellet implantation for contraception.
    Asch RH; Greenblatt RB; Mahesh VB
    Int J Fertil; 1978; 23(2):100-5. PubMed ID: 30717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous implantation of pure crystalline estradiol pellets for conception control.
    Oettinger M; Barak S; Oettinger-Barak O; Ophira E
    Gynecol Obstet Invest; 2005; 59(3):119-25. PubMed ID: 15591820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for a triphasic oral contraceptive.
    Pasquale SA
    J Reprod Med; 1984 Jul; 29(7 Suppl):560-7. PubMed ID: 6481710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility regulation in nursing women. II. Comparative performance of progesterone implants versus placebo and copper T.
    Croxatto HB; Díaz S; Peralta O; Juez G; Casado ME; Salvatierra AM; Durán E
    Am J Obstet Gynecol; 1982 Sep; 144(2):201-8. PubMed ID: 7114130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statement on injectable contraception.
    International Planned Parenthood Federation IPPF
    IPPF Med Bull; 1982 Dec; 16(6):3-4. PubMed ID: 12338511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of biodegradable norethisterone implants as a 6-month contraceptive system.
    Rivera R; Gaitan JR; Ortega M; Flores C; Hernandez A
    Fertil Steril; 1984 Aug; 42(2):228-32. PubMed ID: 6745456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
    Funk S; Miller MM; Mishell DR; Archer DF; Poindexter A; Schmidt J; Zampaglione E;
    Contraception; 2005 May; 71(5):319-26. PubMed ID: 15854630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study].
    Rossmanith WG; Wirth U; Gasser S; Thun B; Steffens D
    Zentralbl Gynakol; 1997; 119(11):538-44. PubMed ID: 9480608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where next with long-acting steroids?
    Potts DM; Siemens AJ
    IPPF Med Bull; 1984 Jun; 18(3):2-3. PubMed ID: 12266285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET) injectable microspheres: a multicenter study.
    Grubb GS; Welch JD; Cole L; Goldsmith A; Rivera R
    Fertil Steril; 1989 May; 51(5):803-10. PubMed ID: 2523322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections.
    Canto de Cetina TE; Luna MO; Cetina Canto JA; Bassol S
    Contraception; 2004 Feb; 69(2):115-9. PubMed ID: 14759615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.